Business Standard

Divi's Labs: Healthy show despite cost hurdles

Even as power costs are likely to remain elevated, higher operating leverage at its new SEZ should result in better margins in FY13

Related News

Divi’s Laboratories fell nearly 8% intraday on Monday post September quarter results that were marginally below expectations and lower sales growth guidance by the management. The bulk drugs and intermediates contract manufacturer posted revenues of Rs 470 crore (up 33%) slightly below what analysts expected. The management also projected a sales growth of 20-25% as compared to 25% plus earlier. analysts say that the September quarter results failed to impress the Street due to high power costs which were at 18% of sales as compared to 15% in the previous quarter and low utilisation levels of the company’s new at Visakhapatnam.

However, most analysts have a ‘buy’ on the stock (it has gained 50% over the last year) as they believe sales momentum is likely to be maintained going ahead on the back of higher capacities and the stock is likely to maintain its premium valuations. Says Deepak Malik of Emkay Global Financial Services, "Divi’s continues to maintain strong performance in the CRAMS space vis-à-vis its peers. Best in class margins and return profile (Return on Invested Capital of over 30%), strong balance sheet (near zero debt), India centric assets coupled with positive cash flow provides incremental comfort to investors.” Analysts have pegged a target price in the range Rs 1,250-Rs 1,400. After the initial fall, the stock recovered some ground. Though it is still down 4% (to Rs 1,138 levels) in two sessions, it is trading at 18 times its estimated FY14 earnings, which is at a discount (12%) to its historic valuations.

Eyeing healthy growth

The company’s forecast of 20-25% for FY13 is backed by growth across the customer synthesis and generics active pharmaceutical ingredient (API) segments, which analysts believe looks sustainable in the medium-term. DSP Merrill Lynch analysts Arvind Bothra and S Arun say that the company is likely to attain a 20-25% revenue growth over the next 6-8 quarters on the back of strong visibility from key clients supported by contribution from the new Vizag SEZ facility. The unit’s contribution, which was at 5% in FY12, is likely to go up to 20% in FY14 as will its utilisation, which stands at 30% currently.

Steady margins

The company recorded margins of 39% (up 335 basis points year-on-year) aided by better product mix, despite high fuel costs. Power costs increased by Rs 15 crore as Divi’s had to buy from the grid at a higher price due to power crisis in Andhra Pradesh. However, going ahead, while power costs are likely to increase, BoAML analysts say their margin assumption at 38% (FY12 margins 37%) is not at risk as higher utilisation at Vizag SEZ would drive operating leverage.

At the net level, profit growth at 11% to Rs 120 crore was lower than estimates due to a Rs 21 crore forex loss. Adjusted for this, net profit was up 26%. Analysts believe earnings are likely to grow annually by 20% over FY12-14.

Read more on:   
|
|
|
|
|

Divi's Labs: Healthy show despite cost hurdles

Even as power costs are likely to remain elevated, higher operating leverage at its new SEZ should result in better margins in FY13

Divi’s Laboratories fell nearly 8% intraday on Monday post September quarter results that were marginally below expectations and lower sales growth guidance by the management. The bulk drugs and intermediates contract manufacturer posted revenues of Rs 470 crore (up 33%) slightly below what analysts expected. The management also projected a FY13 sales growth of 20-25% as compared to 25% plus earlier. SBICAP Securities analysts say that the September quarter results failed to impress the Street due to high power costs which were at 18% of sales as compared to 15% in the previous quarter and low utilisation levels of the company’s new SEZ unit at Visakhapatnam.

Divi’s Laboratories fell nearly 8% intraday on Monday post September quarter results that were marginally below expectations and lower sales growth guidance by the management. The bulk drugs and intermediates contract manufacturer posted revenues of Rs 470 crore (up 33%) slightly below what analysts expected. The management also projected a sales growth of 20-25% as compared to 25% plus earlier. analysts say that the September quarter results failed to impress the Street due to high power costs which were at 18% of sales as compared to 15% in the previous quarter and low utilisation levels of the company’s new at Visakhapatnam.

However, most analysts have a ‘buy’ on the stock (it has gained 50% over the last year) as they believe sales momentum is likely to be maintained going ahead on the back of higher capacities and the stock is likely to maintain its premium valuations. Says Deepak Malik of Emkay Global Financial Services, "Divi’s continues to maintain strong performance in the CRAMS space vis-à-vis its peers. Best in class margins and return profile (Return on Invested Capital of over 30%), strong balance sheet (near zero debt), India centric assets coupled with positive cash flow provides incremental comfort to investors.” Analysts have pegged a target price in the range Rs 1,250-Rs 1,400. After the initial fall, the stock recovered some ground. Though it is still down 4% (to Rs 1,138 levels) in two sessions, it is trading at 18 times its estimated FY14 earnings, which is at a discount (12%) to its historic valuations.

Eyeing healthy growth

The company’s forecast of 20-25% for FY13 is backed by growth across the customer synthesis and generics active pharmaceutical ingredient (API) segments, which analysts believe looks sustainable in the medium-term. DSP Merrill Lynch analysts Arvind Bothra and S Arun say that the company is likely to attain a 20-25% revenue growth over the next 6-8 quarters on the back of strong visibility from key clients supported by contribution from the new Vizag SEZ facility. The unit’s contribution, which was at 5% in FY12, is likely to go up to 20% in FY14 as will its utilisation, which stands at 30% currently.

Steady margins

The company recorded margins of 39% (up 335 basis points year-on-year) aided by better product mix, despite high fuel costs. Power costs increased by Rs 15 crore as Divi’s had to buy from the grid at a higher price due to power crisis in Andhra Pradesh. However, going ahead, while power costs are likely to increase, BoAML analysts say their margin assumption at 38% (FY12 margins 37%) is not at risk as higher utilisation at Vizag SEZ would drive operating leverage.

At the net level, profit growth at 11% to Rs 120 crore was lower than estimates due to a Rs 21 crore forex loss. Adjusted for this, net profit was up 26%. Analysts believe earnings are likely to grow annually by 20% over FY12-14.

image

Read More

ONGC: Street cautious on OVL's acquisition

The largest ever acquisition by ONGC Videsh Ltd (OVL) of $5 billion for 8.4% stake in assets in North Caspian Sea not only increases its reserve base ...

Recommended for you

Advertisements

Quick Links

Market News

Sensex drops 297 points to end below 27,450; Infosys slumps 6%

The 30-share Sensex ended down 297 points at 27,438 and the 50-share Nifty closed 93 points lower at 8,305.

Nifty ends 77 points lower; Infosys' Q4 earnings weigh

The 30-share Sensex provisionally ended down 252 points at 27,483 and the 50-share Nifty ended down 77 points at 8,321.

Gold recovers on wedding season demand, global cues

Metal adds Rs 190 to Rs 27,190 per 10 grams in National Capital, Silver up Rs 250 to Rs 36,500 per kg

Cairn India rebounds from 52-week low

The moved higher by 3% to Rs 221,bouncing back 9% from its 52-week low of Rs 202 touched on the NSE in early morning trade.

CNX IT index drops 3%; Infosys hits three-month low

Infosys,Tech Mahindra, Rolta India, Polaris Consulting, Tata Elxsi and KPIT Techno were down 4%-9% on the NSE.

 

Back to Top